Oryzon Genomics' (MC:ORY) Q316 update revealed good progress on R&D and it reiterated that the preliminary Phase I/IIa data for ORY-1001 is expected to be presented at the American Society of Hematology (ASH) annual meeting on 3 to 6 December 2016. The focus will be on Part 2 of the study, which should include preliminary efficacy information. Oryzon has also made progress with earlier R&D projects, with fresh preclinical ORY-2001 data in September demonstrating potential in a new multiple sclerosis indication, and revealed, in July, a third product, ORY-3001, targeting undisclosed non-oncological indications. Our Oryzon valuation is virtually unchanged at €156m or €5.5/share.
To read the entire report Please click on the pdf File Below